Agilent Technologies, Inc. (NYSE:A) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Agilent Technologies has been rated as a "Moderate Buy" by 15 research firms, with a 12-month target price averaging $148.69.
• Recent upgrades include JPMorgan raising their price target to $165 and UBS increasing it to $170, while Rothschild Redb upgraded the stock to a "strong buy" rating.
• The company declared a quarterly dividend of $0.248 per share, translating to an annual yield of 0.7% and a payout ratio of 23.24%.

Agilent Technologies, Inc. (NYSE:A - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen research firms that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $148.6923.

A has been the subject of several recent research reports. Evercore ISI raised their price target on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an "in-line" rating in a research report on Tuesday. JPMorgan Chase & Co. raised their price target on shares of Agilent Technologies from $155.00 to $165.00 and gave the company an "overweight" rating in a research report on Thursday. Weiss Ratings reissued a "hold (c)" rating on shares of Agilent Technologies in a research report on Wednesday. UBS Group raised shares of Agilent Technologies from a "neutral" rating to a "buy" rating and raised their price target for the company from $130.00 to $170.00 in a research report on Wednesday. Finally, Rothschild Redb raised shares of Agilent Technologies to a "strong-buy" rating in a research report on Wednesday.

Agilent Technologies Stock Down 2.5%

Agilent Technologies stock opened at $136.62 on Friday. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The firm has a 50 day moving average price of $125.04 and a 200 day moving average price of $117.05. The company has a market capitalization of $38.73 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 4.57 and a beta of 1.26.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter last year, the firm earned $1.32 EPS. The firm's revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts expect that Agilent Technologies will post 5.58 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be given a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 30th. Agilent Technologies's dividend payout ratio (DPR) is currently 23.24%.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors have recently modified their holdings of the company. Wedmont Private Capital lifted its position in shares of Agilent Technologies by 2.3% during the 3rd quarter. Wedmont Private Capital now owns 3,630 shares of the medical research company's stock worth $503,000 after purchasing an additional 81 shares during the last quarter. Verdence Capital Advisors LLC lifted its position in shares of Agilent Technologies by 5.0% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company's stock worth $215,000 after purchasing an additional 86 shares during the last quarter. M&T Bank Corp lifted its position in shares of Agilent Technologies by 0.4% during the 2nd quarter. M&T Bank Corp now owns 23,205 shares of the medical research company's stock worth $2,738,000 after purchasing an additional 86 shares during the last quarter. CENTRAL TRUST Co lifted its position in shares of Agilent Technologies by 3.7% during the 2nd quarter. CENTRAL TRUST Co now owns 2,522 shares of the medical research company's stock worth $298,000 after purchasing an additional 89 shares during the last quarter. Finally, Burney Co. lifted its position in shares of Agilent Technologies by 4.8% during the 2nd quarter. Burney Co. now owns 1,957 shares of the medical research company's stock worth $231,000 after purchasing an additional 90 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.